Products Categories
CAS No.: | 322-35-0 |
---|---|
Name: | 2-Amino-3-hydroxy-2'-(2,3,4-trihydroxybenzyl)propionohydrazide |
Molecular Structure: | |
Formula: | C10H15 N3 O5 |
Molecular Weight: | 257.246 |
Synonyms: | DL-Serine,2-[(2,3,4-trihydroxyphenyl)methyl]hydrazide; Serine,2-(2,3,4-trihydroxybenzyl)hydrazide (7CI); Serine,2-(2,3,4-trihydroxybenzyl)hydrazide, DL- (8CI); Benserazide;DL-Seryltrihydroxybenzylhydrazine;N-(DL-Seryl)-N'-(2,3,4-trihydroxybenzyl)hydrazine;N1-(DL-Seryl)-N2-(2,3,4-trihydroxybenzyl)hydrazine; Serazide |
EINECS: | 1312995-182-4 |
Density: | 1.541 g/cm3 |
Boiling Point: | 574.2 °C at 760 mmHg |
Flash Point: | 301 °C |
Hazard Symbols: | R36/37/38:; |
Risk Codes: | Xi:; "> Xi:; |
PSA: | 148.07000 |
LogP: | -0.27410 |
What can I do for you?
Get Best Price
Molecular Formula: C10H15N3O5
Molar mass: 257.2432 g/mol
Density: 1.541 g/cm3
Flash Point: 301 °C
Index of Refraction: 1.678
Boiling Point: 574.2 °C at 760 mmHg
Vapour Pressure: 5.06E-14 mmHg at 25°C
Structure of Benserazide (CAS NO.322-35-0):
XLogP3-AA: -1.3
H-Bond Donor: 7
H-Bond Acceptor: 7
IUPAC Name: 2-Amino-3-hydroxy-N'-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide
Canonical SMILES: C1=CC(=C(C(=C1CNNC(=O)C(CO)N)O)O)O
InChI: InChI=1S/C10H15N3O5/c11-6(4-14)10(18)13-12-3-5-1-2-7(15)9(17)8(5)16/h1-
2,6,12,14-17H,3-4,11H2,(H,13,18)
InChIKey: BNQDCRGUHNALGH-UHFFFAOYSA-N
Benserazide (CAS NO.322-35-0) is not approved for use in the US; carbidopa is used instead for the same purpose. These combinations are also used for the treatment of restless legs syndrome.It is used in the management of Parkinson's disease in combination with L-DOPA (levodopa) as co-beneldopa (BAN), under the brand names Prolopa in Canada and Madopar in the UK, both made by Roche.
Benserazide ,its cas register number is 322-35-0. Benserazide (CAS NO.322-35-0) is a peripherally-acting aromatic L-amino acid decarboxylase (AAAD) or DOPA decarboxylase inhibitor, which is unable to cross the blood-brain barrier, and also can be called N-(DL-Seryl)-N'-(2,3,4-trihydroxybenzyl) Hydrazine ; 2-Amino-3-hydroxy-N'-(2,3,4-trihydroxybenzyl)propanohydrazide ; DL-Serine 2-[(2,3,4-Trihydroxyphenyl)methyl] Hydrazide ; Benserazidum and Serazide .
Benserazide (CAS NO.322-35-0) has little therapeutic effect on its own, and is only administered in combination with levodopa.Most levodopa is decarboxylated to dopamine before it reaches the brain, and since dopamine is unable to cross the blood-brain barrier, this translates to little therapeutic gain with strong peripheral side effects. Benserazide inhibits this decarboxylation.Adverse effects caused by peripheral dopamine. However, benserazide cannot reduce the centrally-mediated side effects of levodopa, particularly dyskinesia.